


Interim Financial Statements (Un-audited)
For the Third Quarter Ended March 31, 2019



Beximco Pharmaceuticals Limited


Beximco Pharmaceuticals Limited and its Subsidiary
Consolidated Statement of Financial Position (Un-audited)
As at March 31, 2019

| | | As at | Taka '000 |
|---|-------|-------------------|------------------------|
| | Notes | March 31, 2019 | As at June 30, 2018 |
| ASSETS | | | |
| Non-Current Assets | | | |
| | | 33,662,200 | 32,394,687 |
| Property, Plant and Equipment- Carrying Value | 5 | 31,734,501 | 30,524,693 |
| Intangible Assets | | 1,345,023 | 1,280,695 |
| Goodwill | | 546,691 | 546,691 |
| Investments in Shares | 6 | 35,985 | 36,508 |
| Other Non-current Assets | | - | 6,100 |
| Current Assets | | | |
| | | 12,836,335 | 11,344,199 |
| Inventories | 7 | 6,348,229 | 5,058,848 |
| Spares & Supplies | | 716,222 | 663,911 |
| Accounts Receivable | | 2,734,805 | 2,761,509 |
| Loans, Advances and Deposits | 8 | 2,224,599 | 2,094,230 |
| Advance Income Tax | | 28,332 | 32,568 |
| Short Term Investment | | 365,420 | 339,397 |
| Cash and Cash Equivalents | 9 | 418,728 | 393,736 |
| TOTAL ASSETS | | 46,498,535 | 43,738,886 |
| SHAREHOLDERS' EQUITY AND LIABILITIES | | | |
| Equity Attributable to the Owners of the Company | | | |
| | | 28,791,268 | 27,081,963 |
| Issued Share Capital | | 4,055,564 | 4,055,564 |
| Share Premium | | 5,269,475 | 5,269,475 |
| Excess of Issue Price over Face Value of GDRs | | 1,689,637 | 1,689,637 |
| Capital Reserve on Merger | | 294,951 | 294,951 |
| Revaluation Surplus | | 1,133,574 | 1,159,278 |
| Unrealized Gain/(Loss) | | 3,834 | 4,357 |
| Retained Earnings | | 16,344,233 | 14,608,701 |
| Non-Controlling Interest | | 269,227 | 269,874 |
| TOTAL EQUITY | | 29,060,495 | 27,351,837 |
| Non-Current Liabilities | | | |
| | | 6,508,511 | 7,368,863 |
| Long Term Borrowings-Net of Current Maturity | 10 A | 2,670,353 | 4,017,425 |
| Liability for Gratuity and WPPF & Welfare Funds | | 1,809,040 | 1,324,166 |
| Deferred Tax Liability | | 2,029,118 | 2,027,272 |
| Current Liabilities and Provisions | | | |
| | | 10,929,529 | 9,018,186 |
| Short Term Borrowings | | 6,720,783 | 5,600,827 |
| Long Term Borrowings-Current Maturity | 10 B | 1,674,051 | 1,568,990 |
| Creditors and Other Payables | | 1,474,045 | 991,713 |
| Accrued Expenses | | 556,288 | 418,477 |
| Dividend Payable | | 54,674 | 4,763 |
| Income Tax Payable | | 449,688 | 433,416 |
| TOTAL EQUITY AND LIABILITIES | | 46,498,535 | 43,738,886 |


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiary
Consolidated Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period Ended March 31, 2019


| | | Taka '000 | | | |
|---|-------|---------------------------|---------------------------|-------------------------|-------------------------|
| | Notes | July 2018 - March 2019 | July 2017 - March 2018 | January - March 2019 | January - March 2018 |
| Net Revenue | | 16,866,369 | 12,859,563 | 5,756,571 | 4,221,024 |
| Cost of Goods Sold | 11 | (8,970,049) | (6,872,812) | (3,030,293) | (2,222,045) |
| Gross Profit | | 7,896,320 | 5,986,751 | 2,726,278 | 1,998,979 |
| Operating Expenses | | (4,166,363) | (3,066,839) | (1,481,464) | (1,070,826) |
| Administrative Expenses | 12 | (570,950) | (442,986) | (205,878) | (151,323) |
| Selling, Marketing and Distribution Expenses | 13 | (3,595,413) | (2,623,853) | (1,275,586) | (919,503) |
| Profit from Operations | | 3,729,957 | 2,919,912 | 1,244,814 | 928,153 |
| Other Income | | 56,770 | 40,569 | 26,239 | 11,760 |
| Finance Cost | | (716,688) | (304,547) | (234,508) | (98,670) |
| Profit Before Contribution to WPPF & Welfare Funds | | 3,070,039 | 2,655,934 | 1,036,545 | 841,243 |
| Contribution to WPPF & Welfare Funds | | (147,700) | (126,473) | (49,862) | (40,059) |
| Profit Before Tax | | 2,922,339 | 2,529,461 | 986,683 | 801,184 |
| Income Tax Expenses | | (686,522) | (608,953) | (238,088) | (198,094) |
| Current Tax | | (703,498) | (604,928) | (214,345) | (188,485) |
| Deferred Tax Income/(Expense) | | 16,976 | (4,025) | (23,743) | (9,609) |
| Profit After Tax | | 2,235,817 | 1,920,508 | 748,595 | 603,090 |
| Profit/(Loss) Attributable to: | | | | | |
| Owners of the Company | | 2,235,596 | 1,920,508 | 747,193 | 603,090 |
| Non-controlling interest | | 221 | - | 1,402 | - |
| | | 2,235,817 | 1,920,508 | 748,595 | 603,090 |
| Other Comprehensive Income-Unrealized Gain/(Loss) | | (523) | 1,440 | 827 | 1,543 |
| Total Comprehensive Income for the Period | | 2,235,294 | 1,921,948 | 749,422 | 604,633 |
| Total Comprehensive Income Attributable to: | | | | | |
| Owners of the Company | | 2,235,073 | 1,921,948 | 748,020 | 604,633 |
| Non-controlling interest | | 221 | - | 1,402 | - |
| | | 2,235,294 | 1,921,948 | 749,422 | 604,633 |
| Earnings Per Share (EPS) | Tk. | 5.51 | 4.74 | 1.84 | 1.49 |
| Number of Shares Used to Compute EPS | Nos. | 405,556,445 | 405,556,445 | 405,556,445 | 405,556,445 |

Note: Comparative prior period information represent Beximco Pharmaceuticals Limited only.


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiary
Consolidated Statement of Changes in Equity (Un-audited)
For the Period Ended March 31, 2019


As at March 31, 2019


Taka' 000

| | Share Capital | Share Premium | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Unrealized Gain/(Loss) | Retained Earnings | Equity attributable to the Owners of the Company | Non-Controlling Interests | Total Equity | |
|--|------------------|------------------|---|---------------------------|---------------------|------------------------|-------------------|--|---------------------------|-------------------|--|
| Balance as on July 01, 2018 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,159,278 | 4,357 | 14,608,701 | 27,081,963 | 269,874 | 27,351,837 | |
| Total Comprehensive Income: | | | | | | | | | | | |
| Profit/(Loss) for the Period | - | - | - | - | - | - | 2,235,596 | 2,235,596 | 221 | 2,235,817 | |
| Other Comprehensive Income/(Loss) | - | - | - | - | - | (523) | - | (523) | - | (523) | |
| Transactions with the Shareholders: | | | | | | | | | | | |
| Cash Dividend | - | - | - | - | - | - | (506,945) | (506,945) | (868) | (507,813) | |
| Adjustment for Depreciation on Revalued Assets | - | - | - | - | (6,881) | - | 6,881 | - | - | - | |
| Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | (18,823) | - | - | (18,823) | - | (18,823) | |
| Balance as on March 31, 2019 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,133,574 | 3,834 | 16,344,233 | 28,791,268 | 269,227 | 29,060,495 | |
| Number of Shares | | | | | | | | | 405,556,445 | | |
| Net Asset Value (NAV) Per Share | | | | | | | | | 70.99 | | |


As at March 31, 2018

| | Share Capital | Share Premium | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Unrealized Gain/(Loss) | Retained Earnings | Total | |
|--|------------------|------------------|---|---------------------------|---------------------|------------------------|-------------------|-------------------|--|
| Balance as on July 01, 2017 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,190,204 | 3,875 | 12,568,720 | 25,072,426 | |
| Total Comprehensive Income : | | | | | | | | | |
| Profit for the Period | - | - | - | - | - | - | 1,920,508 | 1,920,508 | |
| Other Comprehensive Income / (Loss) | - | - | - | - | - | 1,440 | - | 1,440 | |
| Transaction with the Shareholders : | | | | | | | | | |
| Cash Dividend | - | - | - | - | - | - | (506,945) | (506,945) | |
| Adjustment for Depreciation on Revalued Assets | - | - | - | - | (7,787) | - | 7,787 | - | |
| Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | (21,192) | - | - | (21,192) | |
| Balance as on March 31, 2018 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,161,225 | 5,315 | 13,990,070 | 26,466,237 | |
| Number of Shares | | | | | | | | 405,556,445 | |
| Net Asset Value (NAV) Per Share | | | | | | | | Tk. 65.26 | |


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiary
Consolidated Statement of Cash Flows (Un-audited)
For the Period Ended March 31, 2019

| | July 2018- March 2019 | Taka '000 July 2017- March 2018 |
|---|--------------------------|---------------------------------------|
| Cash Flows from Operating Activities : | | |
| Receipts from Customers and Others | 16,967,838 | 12,491,561 |
| Payments to Suppliers and Employees | (12,967,745) | (10,073,250) |
| Cash Generated from Operations | 4,000,093 | 2,418,311 |
| Interest Paid | (716,688) | (304,547) |
| Interest Received | 27,591 | 51,072 |
| Income Tax Paid | (682,990) | (611,096) |
| Net Cash Generated from Operating Activities | 2,628,006 | 1,553,740 |
| Cash Flows from Investing Activities : | | |
| Acquisition of Property, Plant and Equipment | (1,857,053) | (3,748,433) |
| Intangible Assets | (120,122) | (93,995) |
| Investment in Subsidiary | (20,000) | - |
| Disposal of Property, Plant and Equipment | 17,391 | 1,354 |
| Dividend Received | 1,428 | 1,504 |
| (Increase)/Decrease in Short Term Investment | (26,023) | 549,962 |
| Net Cash Used in Investing Activities | (2,004,379) | (3,289,608) |
| Cash Flows from Financing Activities : | | |
| Net Increase /(Decrease) in Long Term Borrowings | (1,260,862) | 1,928,191 |
| Net Increase/(Decrease) in Short Term Borrowings | 1,119,957 | 722,983 |
| Dividend Paid | (457,902) | (502,048) |
| Net Cash Generated from Financing Activities | (598,807) | 2,149,126 |
| Increase/(Decrease) in Cash and Cash Equivalents | 24,820 | 413,258 |
| Cash and Cash Equivalents at Beginning of Period | 393,736 | 275,028 |
| Effect of movement in exchange rates on cash held | 172 | - |
| Cash and Cash Equivalents at End of Period | 418,728 | 688,286 |
| Net Operating Cash Flow Per Share | 6.48 | 3.83 |
| Number of Shares used to compute Net Operating Cash Flow Per Share | 405,556,445 | 405,556,445 |




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited and its Subsidiary
Selected Notes to the Financial Statements (Un-audited)
For the Period Ended March 31, 2019

1 Reporting Entity

1.1. Status of the Company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited company in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka.

1.2. Subsidiaries

1.2. 1. Nuvista Pharma Limited (NPL).

NPL is a non-listed Public Limited Company engaged in manufacturing pharmaceutical products. Beximco Pharmaceuticals Ltd holds 85.22% of paid up shares of the Company.

1.2. 2. Beximco Pharma API Limited (BPL API).

Beximco Pharma API Limited has been formed on 12 December, 2017 as a subsidiary of Beximco Pharma with a Paid up capital of 20 million divided into 2 million shares of Tk. 10 each. The Company intends to set up a facility at API Industrial Park to produce Active Pharmaceutical Ingredients (APIs) for local and export market.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2018 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

3. Basis of Consolidation

The financial statements of the subsidiaries Nuvista Pharma Limited and Beximco Pharma API Ltd. have been consolidated with those of Beximco Pharmaceuticals Limited in accordance with IFRS/BFRS 10: Consolidated Financial Statements. The ownership interest in the companies are adequate enough to establish control and thus BPL meets the conditions as stated in IFRS/BFRS 10: Consolidated Financial Statements to consider them as subsidiaries.

4. Comparative information

Beximco Pharmaceuticals Ltd. Acquired Nuvista Pharma on April 2, 2018. Therefore the comparative prior period (July 2017-March 2018) figures as reported in the Consolidated Statement of Profit or Loss and other Comprehensive Income, Consolidated Statement of Changes in Equity and Consolidated Statement of Cash Flows represent Beximco Pharmaceuticals only. Similarly no comparative information for Beximco Pharma API Limited was available.

Taka '000

| | As at March 31, 2019 | As at June 30, 2018 |
|---|-------------------------|------------------------|
| 5. Property, Plant & Equipment - Carrying Value | | |
| Land | 4,087,829 | 4,067,830 |
| Building and Other Constructions | 7,117,075 | 7,108,792 |
| Plant and Machinery | 13,993,605 | 13,361,895 |
| Furniture and Fixtures | 305,378 | 291,912 |
| Transport and Vehicle | 1,096,273 | 1,070,602 |
| Office Equipment | 590,286 | 567,093 |
| | 27,190,446 | 26,468,124 |
| Less :Accumulated Depreciation | (9,178,322) | (8,556,983) |
| Net Book Value | 18,012,124 | 17,911,141 |
| Capital Work in Progress | 13,722,377 | 12,613,552 |
| Carrying Value | 31,734,501 | 30,524,693 |
| 6. Investment in Shares | | |
| Bangladesh Export Import Co. Ltd. | 3,777 | 4,189 |
| Central Depository Bangladesh Ltd. (CDBL) | 1,569 | 1,569 |
| Biocare Manufacturing SDN.BHD. , Malaysia | 30,639 | 30,750 |
| | 35,985 | 36,508 |
| 7. Inventories | | |
| Finished Goods | 1,296,290 | 864,137 |
| Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit) | 4,959,520 | 4,111,997 |
| Physician Sample | 92,419 | 82,714 |
| | 6,348,229 | 5,058,848 |
| 8. Loans, Advances and Deposits | | |
| Clearing & Forwarding | 302,611 | 162,933 |
| VAT | 344,526 | 219,639 |
| Claims Receivable | 3,266 | 19,643 |
| Security Deposit and Earnest Money | 55,364 | 50,468 |
| Lease Deposit | 17,047 | 17,601 |
| Capital Expenditure / Project | 96,293 | 108,793 |
| Bank Guarantee Margin | 24,975 | 27,005 |
| Advance against Salary | 160,446 | 120,493 |
| Motor Cycle | 204,822 | 180,739 |
| Raw & Packing Material | 559,834 | 735,794 |
| Overseas Liaison Office | 34,983 | 32,699 |
| Others | 420,431 | 418,423 |
| | 2,224,599 | 2,094,230 |
| 9. Cash and Cash Equivalents | | |
| (a) Cash in Hand (Including Imprest Cash) | 157,564 | 192,160 |
| (b) Cash at Bank: | | |
| (i) Current and FC Account | 225,252 | 167,103 |
| (ii) FDR Account | 35,912 | 34,473 |
| | 418,728 | 393,736 |

| | As at March 31, 2019 | Taka '000 As at June 30, 2018 |
|--|--|--|
| 10. Long Term Borrowings | | |
| A. Net of Current Maturity | | |
| Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany | 1,969,938 | 2,809,556 |
| Obligation Under Finance Leases | 236,035 | 280,596 |
| AB Bank | 383,761 | 759,326 |
| Dhaka Bank Limited | 72,534 | 167,947 |
| Uttara Finance and Investments Limited | 8,085 | - |
| | <u>2,670,353</u> | <u>4,017,425</u> |
| B. Current Maturity | | |
| Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany | 858,069 | 852,471 |
| Obligation Under Finance Leases | 171,978 | 201,007 |
| AB Bank | 517,208 | 400,342 |
| Dhaka Bank Limited | 125,235 | 115,170 |
| Uttara Finance and Investments Limited | 1,561 | - |
| | <u>1,674,051</u> | <u>1,568,990</u> |
| C. Outstanding foreign currency loan from ODDO BHF Bank, Germany has been converted to functional currency at the exchange rate prevailing on the date of Statement of Financial Position. Such conversion resulted an exchange fluctuation loss of Tk. 18,850,471. | | |
| | For the period July 2018 - March 2019 | For the period July 2017 - March 2018 |
| 11. Cost of Goods Sold | | |
| Materials | 6,673,290 | 5,041,179 |
| Factory Overhead | 1,714,902 | 1,307,625 |
| Depreciation | 581,857 | 524,008 |
| | <u>8,970,049</u> | <u>6,872,812</u> |
| 12. Administrative Expenses | | |
| Salary & Allowances | 302,973 | 224,306 |
| Repairs & Maintenance | 37,390 | 30,248 |
| Travelling & Conveyance | 21,075 | 19,022 |
| Company Secretarial, Regulatory Fee and AGM Expense | 20,032 | 25,472 |
| Depreciation | 22,428 | 20,265 |
| Other Expenses | 167,052 | 123,673 |
| | <u>570,950</u> | <u>442,986</u> |
| 13. Selling, Marketing and Distribution Expenses | | |
| Salary & Allowances | 1,302,648 | 914,842 |
| Travelling & Conveyance | 394,622 | 312,506 |
| Market Research & New Products | 43,327 | 37,109 |
| Sample, Literature & News Letter | 444,574 | 351,528 |
| Sales & Market Promotion Expenses | 493,027 | 383,857 |
| Distribution Commission | 212,921 | 195,213 |
| Delivery Expense | 292,439 | 190,737 |
| Depreciation and Amortization | 102,734 | 59,293 |
| Export Insurance, Freight and C & F Expenses | 222,675 | 58,909 |
| Other Expenses | 86,446 | 119,859 |
| | <u>3,595,413</u> | <u>2,623,853</u> |

Taka '000

For the period
July 2018 - March 2019For the period
July 2017 - March 2018**14. Deferred Tax Income/(Expense)**

Deferred Tax is arrived at as follows :


| | | |
|--|------------------|------------------|
| Property, Plant & Equipment (Difference in book value & Tax base) | 8,815,119 | 8,125,402 |
| Deferred Liability (Gratuity) | (943,921) | (613,870) |
| Temporary Difference | 7,871,198 | 7,511,532 |
| Tax Rate | 25% | 25% |
| Deferred Tax Liability at end of the period | 2,029,118 | 1,877,883 |
| Deferred Tax Liability at beginning of the period | 2,027,271 | 1,852,666 |
| Change in Deferred Tax Liability | 1,847 | 25,217 |
| Deferred Tax on Revaluation Surplus | (18,823) | (21,192) |
| Deferred Tax Income/(Expense) | 16,976 | (4,025) |

15. Reconciliation of Net Profit with Cash Flows from Operating Activities

| | | |
|-------------------------|------------------|------------------|
| Profit after Tax | 2,235,817 | 1,920,508 |
|-------------------------|------------------|------------------|

Adjustment to reconcile net profit to net cash Generated from Operating Activities :

| | | |
|---|------------------|--------------------|
| Non-cash Expenses : | 1,174,917 | 681,111 |
| Depreciation | 651,225 | 579,014 |
| Amortization | 55,794 | 24,552 |
| Gratuity & WPPF | 484,874 | 73,520 |
| Deferred tax | (16,976) | 4,025 |
| Non-operating items: | 15,880 | 19,931 |
| Loss on sale of Fixed Assets | (1,370) | 846 |
| Technology Transfer Income - Biocare manufacturing SDN. BHD. Malaysia | - | (18,146) |
| Dividend Income | (1,428) | (1,504) |
| Exchange rate fluctuation loss on Foreign Currency Bank Loan | 18,850 | 38,735 |
| Effect of movement in exchange rates on cash held | (172) | - |
| Changes in working Capital | (798,608) | (1,067,810) |
| (Increase)/Decrease in Inventories | (1,289,381) | (305,227) |
| (Increase)/Decrease in Spares & Supplies | (52,311) | 6,820 |
| (Increase)/Decrease in Accounts Receivable | 26,705 | (377,431) |
| (Increase)/Decrease in Loans, Advances & Deposits | (124,269) | (1,070,265) |
| (Increase)/Decrease in Advance Income Tax | 4,236 | - |
| Increase/(Decrease) in Creditors and Other Payables | 482,330 | 471,644 |
| Increase/(Decrease) in Accrued Expenses | 137,811 | 212,817 |
| Increase/(Decrease) in Income Tax Payable | 16,272 | (6,168) |
| Net cash Generated from Operating Activities | 2,628,006 | 1,553,740 |




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary


Beximco Pharmaceuticals Limited
Statement of Financial Position (Un-audited)
As at March 31, 2019

| | | Taka '000 | |
|---|--------------|---------------------------------|--------------------------------|
| ASSETS | Notes | As at March 31, 2019 | As at June 30, 2018 |
| Non-Current Assets | | 32,664,911 | 31,332,494 |
| Property, Plant and Equipment- Carrying Value | 3 | 29,871,067 | 28,645,105 |
| Intangible Assets | | 612,673 | 525,695 |
| Investment in Subsidiary | | 2,145,186 | 2,125,186 |
| Investment in Shares | 4 | 35,985 | 36,508 |
| Current Assets | | 12,353,251 | 10,832,521 |
| Inventories | 5 | 5,962,628 | 4,665,449 |
| Spares & Supplies | | 704,230 | 654,781 |
| Accounts Receivable | | 2,754,746 | 2,736,944 |
| Loans, Advances and Deposits | 6 | 2,176,112 | 2,066,841 |
| Short Term Investment | | 365,420 | 339,397 |
| Cash and Cash Equivalents | 7 | 390,115 | 369,109 |
| TOTAL ASSETS | | 45,018,162 | 42,165,015 |
| EQUITY AND LIABILITIES | | | |
| Shareholders' Equity | | 28,812,421 | 27,104,390 |
| Issued Share Capital | | 4,055,564 | 4,055,564 |
| Share Premium | | 5,269,475 | 5,269,475 |
| Excess of Issue Price over Face Value of GDRs | | 1,689,637 | 1,689,637 |
| Capital Reserve on Merger | | 294,951 | 294,951 |
| Revaluation Surplus | | 1,133,574 | 1,159,278 |
| Unrealised Gain/(Loss) | | 3,834 | 4,357 |
| Retained Earnings | | 16,365,386 | 14,631,128 |
| Non-Current Liabilities | | 6,179,022 | 6,963,764 |
| Long Term Borrowings-Net of Current Maturity | 8 A | 2,589,734 | 3,849,479 |
| Liability for Gratuity and WPPF & Welfare Funds | | 1,703,167 | 1,224,462 |
| Deferred Tax Liability | | 1,886,121 | 1,889,823 |
| Current Liabilities and Provisions | | 10,026,719 | 8,096,861 |
| Short Term Borrowings | | 6,127,795 | 4,962,098 |
| Long Term Borrowings-Current Maturity | 8 B | 1,547,255 | 1,453,820 |
| Creditors and Other Payables | | 1,413,151 | 939,538 |
| Accrued Expenses | | 434,386 | 303,448 |
| Dividend Payable | | 54,444 | 4,541 |
| Income Tax Payable | | 449,688 | 433,416 |
| TOTAL EQUITY AND LIABILITIES | | 45,018,162 | 42,165,015 |


A S F Rahman
 Chairman


Salman F Rahman
 Vice Chairman


Nazmul Hassan
 Managing Director


Ali Nawaz
 Chief Financial Officer


Mohammad Asad Ullah, FCS
 Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Profit or Loss and Other Comprehensive Income (Un-audited)
For the Period July 2018 - March 2019

Taka '000

| | Notes | July 2018 - March 2019 | July 2017 - March 2018 | January - March 2019 | January - March 2018 |
|---|-------|---------------------------|---------------------------|-------------------------|-------------------------|
| Net Sales Revenue | | 15,673,095 | 12,859,563 | 5,332,590 | 4,221,024 |
| Cost of Goods Sold | 9 | (8,362,855) | (6,872,812) | (2,824,587) | (2,222,045) |
| Gross Profit | | 7,310,240 | 5,986,751 | 2,508,003 | 1,998,979 |
| Operating Expenses | | (3,740,617) | (3,066,839) | (1,329,016) | (1,070,826) |
| Administrative Expenses | 10 | (522,837) | (442,986) | (188,536) | (151,323) |
| Selling, Marketing and Distribution Expenses | 11 | (3,217,780) | (2,623,853) | (1,140,480) | (919,503) |
| Profit from Operations | | 3,569,623 | 2,919,912 | 1,178,987 | 928,153 |
| Other Income | | 122,352 | 40,569 | 49,353 | 11,760 |
| Finance Cost | | (645,860) | (304,547) | (213,172) | (98,670) |
| Profit Before Contribution to WPPF & Welfare Funds | | 3,046,115 | 2,655,934 | 1,015,168 | 841,243 |
| Contribution to WPPF & Welfare Funds | | (145,053) | (126,473) | (48,341) | (40,059) |
| Profit Before Tax | | 2,901,062 | 2,529,461 | 966,827 | 801,184 |
| Income Tax Expenses | | (666,740) | (608,953) | (227,721) | (198,094) |
| Current Tax | | (689,265) | (604,928) | (205,554) | (188,485) |
| Deferred Tax Income/(Expense) | 12 | 22,525 | (4,025) | (22,167) | (9,609) |
| Profit After Tax | | 2,234,322 | 1,920,508 | 739,106 | 603,090 |
| Other Comprehensive Income-Unrealized Gain/(Loss) | | (523) | 1,440 | 827 | 1,543 |
| Total Comprehensive Income | | 2,233,799 | 1,921,948 | 739,933 | 604,633 |


| | | | | | |
|--------------------------------------|------|-------------|-------------|-------------|-------------|
| Earnings Per Share (EPS) | Tk. | 5.51 | 4.74 | 1.82 | 1.49 |
| Number of Shares Used to Compute EPS | Nos. | 405,556,445 | 405,556,445 | 405,556,445 | 405,556,445 |


A S F Rahman


Chairman


Salman F Rahman

Vice Chairman


Nazmul Hassan

Managing Director


Ali Nawaz

Chief Financial Officer


Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Changes in Equity (Un-audited)
For the Period July 2018 - March 2019


As at March 31, 2019

Taka '000

| | Share Capital | Share Premium | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Unrealised Gain / (Loss) | Retained Earnings | Total | |
|--|------------------|------------------|---|---------------------------|---------------------|--------------------------|-------------------|-------------------|--------------|
| Balance as on July 01, 2018 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,159,278 | 4,357 | 14,631,128 | 27,104,390 | |
| Total Comprehensive Income : | | | | | | | | | |
| Profit for the Period | - | - | - | - | - | - | 2,234,322 | 2,234,322 | |
| Other Comprehensive Income / (Loss) | - | - | - | - | - | (523) | - | (523) | |
| Transaction with the Shareholders : | | | | | | | | | |
| Cash Dividend | - | - | - | - | - | - | (506,945) | (506,945) | |
| Adjustment for Depreciation on Revalued Assets | - | - | - | - | (6,881) | - | 6,881 | - | |
| Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | (18,823) | - | - | (18,823) | |
| Balance as on March 31, 2019 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,133,574 | 3,834 | 16,365,386 | 28,812,421 | |
| Number of Shares | | | | | | | | 405,556,445 | |
| Net Asset Value (NAV) Per Share | | | | | | | | Tk. | 71.04 |


As at March 31, 2018

| | Share Capital | Share Premium | Excess of Issue Price over Face Value of GDRs | Capital Reserve on Merger | Revaluation Surplus | Unrealised Gain / (Loss) | Retained Earnings | Total | |
|--|------------------|------------------|---|---------------------------|---------------------|--------------------------|-------------------|-------------------|--------------|
| Balance as on July 01, 2017 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,190,204 | 3,875 | 12,568,720 | 25,072,426 | |
| Total Comprehensive Income : | | | | | | | | | |
| Profit for the Period | - | - | - | - | - | - | 1,920,508 | 1,920,508 | |
| Other Comprehensive Income / (Loss) | - | - | - | - | - | 1,440 | - | 1,440 | |
| Transaction with the Shareholders : | | | | | | | | | |
| Cash Dividend | - | - | - | - | - | - | (506,945) | (506,945) | |
| Adjustment for Depreciation on Revalued Assets | - | - | - | - | (7,787) | - | 7,787 | - | |
| Adjustment for Deferred Tax on Revalued Assets | - | - | - | - | (21,192) | - | - | (21,192) | |
| Balance as on March 31, 2018 | 4,055,564 | 5,269,475 | 1,689,637 | 294,951 | 1,161,225 | 5,315 | 13,990,070 | 26,466,237 | |
| Number of Shares | | | | | | | | 405,556,445 | |
| Net Asset Value (NAV) Per Share | | | | | | | | Tk. | 65.26 |


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Statement of Cash Flows (Un-audited)
For the Period July 2018 - March 2019


| | July 2018- March 2019 | Taka '000 July 2017 - March 2018 |
|---|--------------------------|--|
| Cash Flows from Operating Activities : | | |
| Receipts from Customers and Others | 15,765,961 | 12,491,561 |
| Payments to Suppliers and Employees | (12,020,304) | (10,073,250) |
| Cash Generated from Operations | 3,745,657 | 2,418,311 |
| Interest Paid | (645,860) | (304,547) |
| Interest Received | 27,591 | 51,072 |
| Income Tax Paid | (672,994) | (611,096) |
| Net Cash Generated from Operating Activities | 2,454,394 | 1,553,740 |
| Cash Flows from Investing Activities : | | |
| Acquisition of Property, Plant and Equipment | (1,809,606) | (3,748,433) |
| Intangible Assets | (120,122) | (93,995) |
| Investment in Subsidiary | (20,000) | - |
| Disposal of Property, Plant and Equipment | 17,268 | 1,354 |
| Dividend Received | 1,428 | 1,504 |
| (Increase)/Decrease in Short Term Investment | (26,023) | 549,962 |
| Net Cash Used in Investing Activities | (1,957,055) | (3,289,608) |
| Cash Flows from Financing Activities : | | |
| Net Increase/(Decrease) in Long Term Borrowings | (1,185,160) | 1,928,191 |
| Net Increase/(Decrease) in Short Term Borrowings | 1,165,697 | 722,983 |
| Dividend Paid | (457,042) | (502,048) |
| Net Cash Generated from Financing Activities | (476,505) | 2,149,126 |
| Increase / (Decrease) in Cash and Cash Equivalents | 20,834 | 413,258 |
| Cash and Cash Equivalents at Beginning of Period | 369,109 | 275,028 |
| Effect of movement in exchange rates on cash held | 172 | - |
| Cash and Cash Equivalents at End of Period | 390,115 | 688,286 |

| | | | |
|--|------------|-------------|-------------|
| Net Operating Cash Flow Per Share | Tk. | 6.05 | 3.83 |
| Number of Shares Used to Compute Net Operating Cash Flow Per Share | | 405,556,445 | 405,556,445 |


A S F Rahman
Chairman


Salman F Rahman
Vice Chairman


Nazmul Hassan
Managing Director


Ali Nawaz
Chief Financial Officer


Mohammad Asad Ullah, FCS
Executive Director & Company Secretary

Beximco Pharmaceuticals Limited
Selected Notes to the Financial Statements (Un-audited)
For the Period July 2018 - March 2019

1. Reporting Entity

1.1 About the company

Beximco Pharmaceuticals Limited (BPL/ the Company) was incorporated as a public limited company in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company was listed with Dhaka Stock Exchange in 1985 and with Chittagong Stock Exchange on its debut in 1995. In 2005, BPL got enlisted with the Alternative Investment Market (AIM) of the London Stock Exchange through issuance of Global Depository Receipts (GDRs). Shares of the Company are traded in Dhaka and Chittagong Stock Exchanges of Bangladesh and its GDRs in AIM of the London Stock Exchange.

The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The industrial units are located at Tongi and Kaliakoir of Gazipur district – vicinities close to the capital city Dhaka.

1.2 Nature of Business

The company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products including life saving intravenous fluids, Therapeutic Nutrition Products and Active Pharmaceutical Ingredients (APIs). Products of the company are sold in domestic and international markets. The company also provides contract manufacturing services.

2. Basis of Preparation of Financial Statements

These interim financial statements should be read in conjunction with the Financial Statements for the Year ended June 30, 2018 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

3. Property, Plant & Equipment - Carrying Value

| | As at March 31, 2019 | Taka '000 As at June 30, 2018 |
|----------------------------------|---------------------------------|--|
| Land | 3,343,741 | 3,343,741 |
| Building and Other Constructions | 6,794,567 | 6,794,567 |
| Plant and Machinery | 12,757,584 | 12,154,522 |
| Furniture and Fixtures | 259,364 | 247,566 |
| Transport and Vehicle | 948,805 | 926,149 |
| Office Equipment | 564,510 | 542,240 |
| | 24,668,571 | 24,008,785 |
| Less :Accumulated Depreciation | (8,506,589) | (7,961,275) |
| Net Book Value | 16,161,982 | 16,047,510 |
| Capital Work in Progress | 13,709,085 | 12,597,595 |
| Carrying Value | 29,871,067 | 28,645,105 |

Taka '000

| | As at March 31, 2019 | As at June 30, 2018 |
|---|-------------------------|------------------------|
| 4. Investment in Shares | | |
| Bangladesh Export Import Co. Ltd. | 3,777 | 4,189 |
| Central Depository Bangladesh Ltd. (CDBL) | 1,569 | 1,569 |
| Biocare Manufacturing SDN.BHD. , Malaysia | 30,639 | 30,750 |
| | <u>35,985</u> | <u>36,508</u> |
| 5. Inventories | | |
| Finished Goods | 1,173,977 | 744,139 |
| Raw and Packing Materials (Including Work in Process, Laboratory Chemicals, R & D Materials and Material in Transit) | 4,696,232 | 3,838,596 |
| Physician Sample | 92,419 | 82,714 |
| | <u>5,962,628</u> | <u>4,665,449</u> |
| 6. Loans, Advances and Deposits | | |
| Clearing & Forwarding | 302,611 | 162,933 |
| VAT | 318,444 | 188,083 |
| Claims Receivable | 3,266 | 19,643 |
| Security Deposit and Earnest Money | 51,576 | 47,837 |
| Lease Deposit | 17,047 | 17,601 |
| Capital Expenditure / Project | 96,293 | 108,793 |
| Bank Guarantee Margin | 24,975 | 27,005 |
| Advance against Salary | 149,619 | 116,814 |
| Motor Cycle | 204,822 | 180,739 |
| Raw & Packing Material | 559,834 | 735,794 |
| Overseas Liaison Office | 34,983 | 32,699 |
| Others | 412,642 | 428,900 |
| | <u>2,176,112</u> | <u>2,066,841</u> |
| 7. Cash and Cash Equivalents | | |
| (a) Cash in Hand (Including Imprest Cash) | 157,216 | 191,916 |
| (b) Cash at Bank: | | |
| (i) Current and FC Account | 196,987 | 142,719 |
| (ii) FDR Account | 35,912 | 34,474 |
| | <u>390,115</u> | <u>369,109</u> |
| 8. Long Term Borrowings | | |
| A. Net of Current Maturity | | |
| Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany | 1,969,938 | 2,809,557 |
| Obligation Under Finance Leases | 236,035 | 280,596 |
| AB Bank | 383,761 | 759,326 |
| | <u>2,589,734</u> | <u>3,849,479</u> |
| B. Current Maturity | | |
| Project Loan - ODDO BHF Aktiengesellschaft, Frankfurt, Germany | 858,069 | 852,471 |
| Obligation Under Finance Leases | 171,978 | 201,007 |
| AB Bank | 517,208 | 400,342 |
| | <u>1,547,255</u> | <u>1,453,820</u> |

C. Outstanding foreign currency loan from ODDO BHF Bank, Germany has been converted to functional currency at the exchange rate prevailing on the date of Statement of Financial Position. Such conversion resulted an exchange fluctuation loss of Tk. 18,850,471.

Taka '000

For the Period
July 2018 - March 2019For the Period
July 2017 - March 2018**9. Cost of Goods Sold**

| | | |
|------------------|------------------|------------------|
| Materials | 6,379,086 | 5,041,179 |
| Factory Overhead | 1,469,981 | 1,307,625 |
| Depreciation | 513,788 | 524,008 |
| | 8,362,855 | 6,872,812 |

10. Administrative Expenses

| | | |
|---|----------------|----------------|
| Salary & Allowances | 274,339 | 224,306 |
| Repairs & Maintenance | 34,673 | 30,248 |
| Travelling & Conveyance | 20,831 | 19,022 |
| Company Secretarial, Regulatory Fee and AGM Expense | 19,625 | 25,472 |
| Depreciation | 19,870 | 20,265 |
| Other Expenses | 153,499 | 123,673 |
| | 522,837 | 442,986 |

11. Selling, Marketing and Distribution Expenses

| | | |
|--|------------------|------------------|
| Salary & Allowances | 1,127,416 | 914,842 |
| Travelling & Conveyance | 345,311 | 312,506 |
| Market Research & New Products | 43,327 | 37,109 |
| Sample, Literature & News Letter | 409,920 | 351,528 |
| Sales & Market Promotion Expenses | 426,985 | 383,857 |
| Distribution Commission | 212,921 | 195,213 |
| Delivery Expense | 292,439 | 190,737 |
| Depreciation and Amortization | 67,207 | 59,293 |
| Export Insurance, Freight and C & F Expenses | 222,675 | 58,909 |
| Other Expenses | 69,579 | 119,859 |
| | 3,217,780 | 2,623,853 |

12. Deferred Tax Income/(Expense)

Deferred Tax is arrived at as follows :

| | | |
|--|------------------|------------------|
| Property, Plant & Equipment (Difference in book value & Tax base) | 8,386,777 | 8,125,402 |
| Deferred Liability (Gratuity) | (842,292) | (613,870) |
| Temporary Difference | 7,544,485 | 7,511,532 |
| Tax Rate | 25% | 25% |
| Deferred Tax Liability at end of the period | 1,886,121 | 1,877,883 |
| Deferred Tax Liability at beginning of the period | 1,889,823 | 1,852,666 |
| Change in Deferred Tax Liability | (3,702) | 25,217 |
| Deferred Tax on Revaluation Surplus | (18,823) | (21,192) |
| Deferred Tax Income/(Expense) | 22,525 | (4,025) |

Taka '000

For the Period
July 2018 - March 2019For the Period
July 2017 - March 2018**13. Reconciliation of Net Profit with Cash Flows from Operating Activities**

| | | |
|---|------------------|--------------------|
| Profit after Tax | 2,234,322 | 1,920,508 |
| Adjustment to reconcile net profit to net cash Generated from Operating Activities : | | |
| Non-cash Expenses : | 1,057,045 | 681,111 |
| Depreciation | 567,721 | 579,014 |
| Amortization | 33,144 | 24,552 |
| Gratuity & WPPF | 478,705 | 73,520 |
| Deferred Tax | (22,525) | 4,025 |
| Non-operating items: | 15,905 | 19,931 |
| Technology Transfer Income - Biocare manufacturing SDN. BHD. Malaysia | - | (18,146) |
| Exchange rate fluctuation loss on Foreign Currency Bank Loan | 18,850 | 38,735 |
| Dividend Income | (1,428) | (1,504) |
| Loss /(Gain) on sale of Fixed Assets | (1,345) | 846 |
| Effect of movement in exchange rates on cash held | (172) | - |
| Changes in Working Capital | (852,878) | (1,067,810) |
| (Increase)/Decrease in Inventories | (1,297,179) | (305,227) |
| (Increase)/Decrease in Spares & Supplies | (49,449) | 6,820 |
| (Increase)/Decrease in Accounts Receivable | (17,802) | (377,431) |
| (Increase)/Decrease in Loans, Advances & Deposits | (109,271) | (1,070,265) |
| Increase/(Decrease) in Creditors and Other Payables | 473,613 | 471,644 |
| Increase/(Decrease) in Accrued Expenses | 130,938 | 212,817 |
| Increase/(Decrease) in Income Tax Payable | 16,272 | (6,168) |
| Net cash Generated from Operating Activities | 2,454,394 | 1,553,740 |




A S F Rahman
Chairman



Salman F Rahman
Vice Chairman



Nazmul Hassan
Managing Director



Ali Nawaz
Chief Financial Officer



Mohammad Asad Ullah, FCS
Executive Director & Company Secretary